{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:55:02Z","timestamp":1787064902987,"version":"build-2736575974"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG15232, IG16985"],"award-info":[{"award-number":["IG15232, IG16985"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01492","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:35:17Z","timestamp":1529886917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["V\u03b39V\u03b42 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression"],"prefix":"10.3389","volume":"9","author":[{"given":"Barbara","family":"Castella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Foglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Massaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1007\/s00018-011-0704-8","article-title":"V\u03b39V\u03b42 T cell-based immunotherapy in hematological malignancies: from bench to bedside","volume":"68","author":"Castella","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","article-title":"The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V\u03b39V\u03b42 T cells","volume":"40","author":"Sandstrom","year":"2014","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/eji.1830270422","article-title":"Comparative analysis of alpha beta and gamma delta T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate","volume":"27","author":"Wesch","year":"1997","journal-title":"Eur J Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiplemyeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1359\/JBMR.0301230","article-title":"Statins prevent bisphosphonate-induced gammadelta-T-cell proliferation and activation in vitro","volume":"19","author":"Thompson","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15663","DOI":"10.1038\/ncomms15663","article-title":"The ATP-binding cassette transporter A1 regulates phosphoantigen release and V\u03b39V\u03b42 T cell activation by dendritic cells","volume":"8","author":"Castella","year":"2017","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"\u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","article-title":"Phase-I study of innacell \u03b3\u03b4, an autologous cell-therapy product highly enriched in \u03b39\u03b42 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma","volume":"57","author":"Bennouna","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","article-title":"Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded \u03b3\u03b4 T cells: a phase I clinical study","volume":"34","author":"Sakamoto","year":"2011","journal-title":"J Immunother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2174\/138920109787847493","article-title":"Multiple myeloma bone marrow niche","volume":"10","author":"BasaK","year":"2009","journal-title":"Curr Pharm Biotechnol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clml.2016.08.003","article-title":"The T cell in myeloma","volume":"16","author":"Joshua","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3389\/fimmu.2017.01401","article-title":"Current advances in \u03b3\u03b4 T cell-based tumor immunotherapy","volume":"8","author":"Lo Presti","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.4049\/jimmunol.1000681","article-title":"Phosphoantigens overcome human TCRV\u03b39+ \u03b3\u03b4 cell immunosuppression by TGF-\u03b2: relevance for cancer immunotherapy","volume":"184","author":"Capietto","year":"2010","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2326-6066.CIR-15-0146","article-title":"IFN-\u03b3-dependent interactions between ICAM-1 and LFA-1 counteract prostaglandin E2-mediated Inhibition of antitumor CTL responses","volume":"4","author":"Basingab","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/1078-0432.CCR-15-0420","article-title":"Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy","volume":"21","author":"Zhai","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","article-title":"Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma","volume":"23","author":"Manier","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1038\/leu.2017.102","article-title":"Proteomic characterization of human multiple myeloma bone marrow extracellular matrix","volume":"31","author":"Glavey","year":"2017","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.leukres.2004.06.003","article-title":"High Th1\/Th2 ratio in patients with multiple myeloma","volume":"29","author":"Ogawara","year":"2005","journal-title":"Leuk Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clim.2010.12.010","article-title":"Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges","volume":"140","author":"Dhodapkar","year":"2011","journal-title":"Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2006-09-044321","article-title":"Enhanced ability of dendritic cells to stimulate innate and adaptive immunity upon short-term incubation with zoledronic acid","volume":"110","author":"Fiore","year":"2007","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1002514","article-title":"Immune modulation by zoledronic acid in human myeloma: an advantageous cross talk between V\u03b39V\u03b42 T cells, \u03b1\u03b2 CD8+ T cells, regulatory T cells, and dendritic cells","volume":"187","author":"Castella","year":"2011","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1047580","DOI":"10.1080\/2162402X.2015.1047580","article-title":"Anergic bone marrow V9V2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma","volume":"4","author":"Castella","year":"2015","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2017.136","article-title":"Hallmarks of response to immune checkpoint blockade","volume":"117","author":"Cogdill","year":"2017","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.jmb.2018.05.030","article-title":"Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer","volume":"430","author":"Borcherding","year":"2018","journal-title":"J Mol Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"48360","DOI":"10.18632\/oncotarget.10235","article-title":"PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells","volume":"7","author":"Guo","year":"2016","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitor: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1\u2013PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8010-8010","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and safety analysis","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.V128.22.2119.2119","article-title":"Pembrolizumab in combination with pomalidomide and dexamethasone (PEMBRO\/POM\/DEX) for pomalidomide exposed relapsed or refractory multiple myeloma","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V126.23.1838.1838","article-title":"First interim results of a phase I\/II study of lenalidomide in combination with anti-PD-1 monoclonal antibody MDV9300 (CT-011) in patients with relapsed\/refractory multiple myeloma","volume":"126","author":"Efebera","year":"2015","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri1349","article-title":"Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity","volume":"4","author":"Chen","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/eji.201040959","article-title":"Expression and function of PD-1 in human gd T cells that recognize phosphoantigens","volume":"41","author":"Iwasaki","year":"2011","journal-title":"Eur J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93179","article-title":"Adoptively transferred V\u03b39V\u03b42 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model","volume":"2","author":"Zumwalde","year":"2017","journal-title":"JCI Insight"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/leu.2011.122","article-title":"The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma","volume":"25","author":"Martin","year":"2011","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1a, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy038","article-title":"Oxygen-dependent regulation of immune-checkpoint mechanisms","author":"Ohta","year":"2018","journal-title":"Int Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs","volume":"19","author":"Allard","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma","volume":"3","author":"Horenstein","year":"2016","journal-title":"Mol Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologicmalignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4049\/jimmunol.1701262","article-title":"Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment","volume":"200","author":"Gorris","year":"2018","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","article-title":"\u03b3\u03b4 T cells support pancreatic oncogenesis by restraining \u03b1\u03b2 T cell activation","volume":"166","author":"Daley","year":"2016","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development?","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.4049\/jimmunol.0901334","article-title":"Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation","volume":"183","author":"Casetti","year":"2009","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CJI.0b013e3181b51447","article-title":"Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells","volume":"33","author":"Traxlmayr","year":"2010","journal-title":"J Immunother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1379642","DOI":"10.1080\/2162402X.2017.1379642","article-title":"IL-21 promotes the development of a CD73-positive V\u03b39V\u03b42 T cell regulatory population","volume":"7","author":"Barjon","year":"2017","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbrc.2016.10.098","article-title":"Characterization of \u03b3\u03b4 regulatory T cells from peripheral blood in patients with multiple myeloma","volume":"480","author":"Ma","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B72","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood.V98.9.2817","article-title":"Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(\u2212) compartment","volume":"98","author":"Sze","year":"2001","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.it.2017.06.004","article-title":"The ambiguous role of \u03b3\u03b4 T lymphocytes in antitumor immunity","volume":"38","author":"Chitadze","year":"2017","journal-title":"Trends Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e1208878","DOI":"10.1080\/2162402X.2016.1208878","article-title":"Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of gd17 T cells in melanoma","volume":"5","author":"Douguet","year":"2016","journal-title":"Oncoimmunology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T18:50:26Z","timestamp":1571511026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2018.01492"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01492","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"article-number":"1492"}}